Profile of neratinib and its potential in the treatment of breast cancer

Share this content:

the ONA take:

Neratinib is a potent, irreversible, pan–human epidermal growth factor receptor (HER) inhibitor that has demonstrated promising activity in both preclinical and clinical trials with a tolerable safety profile in humans, according to a review published in the journal Breast Cancer: Targets and Therapy.

Neratinib is being studied in a number of subtypes of breast cancer. Several studies have shown that neratinib is most effective in HER2-positive breast cancer compared with other subtypes, and may control central nervous system (CNS) metastases in patients with HER2-positive disease; however, preliminary data showed a CNS overall response rate of only 7.5%.

Studies have demonstrated activity with both neratinib monotherapy and in combination with chemotherapy. In a study evaluating neratinib monotherapy in patients with HER2-positive advanced breast cancer, the 16-week progression-free survival rate was 59% and 78% in those who had received prior trastuzumab and in those who were trastuzumab-naïve. The tyrosine kinase inhibitor has also provided clinical benefit in combination with paclitaxel with or without trastuzumab.

In regard to safety, the most common adverse events associated with neratinib use were diarrhea, nausea, fatigue, vomiting, neutropenia, and anorexia.

Neratinib is also being evaluated in various other tumor types, including bladder, colorectal, and non-small cell lung cancers.

Breast Cancer: Targets and Therapy
Breast Cancer: Targets and Therapy

Abstract: The HER (ErbB) receptor tyrosine kinase receptors are implicated in many cancers and several anti-HER treatments are now approved. In recent years, a new group of compounds that bind irreversibly to the adenosine triphosphate binding pocket of HER receptors have been developed. One of these compounds, neratinib, has passed preclinical phases and is currently undergoing various clinical trials. This manuscript reviews the preclinical as well as clinical data on neratinib. As a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. Neratinib has been shown to be effective against HER2-overexpressing or mutant tumors in vitro and in vivo. Neratinib is currently being investigated in various clinical trials in breast cancers and other solid tumors, including those with HER2 mutation. Earlier studies have already shown promising clinical activity for neratinib. However, more translational research is required to investigate biomarkers that could help to predict response and resistance for selection of appropriate patients for treatment with neratinib, either as monotherapy or in combination with other drug(s).

Keywords: neratinib, HKI 272, pan-HER inhibitor, irreversible tyrosine kinase inhibitor, HER (ErbB), breast cancer


The family of HER (ErbB) receptor tyrosine kinases consists of four members, ie, epidermal growth factor receptors [EGFR (HER1 or ErbB1), HER2 (ErbB2, neu), HER3 (ErbB3), and HER4 (ErbB4)].Overexpression, mutation, or aberrant activity of these receptors has been implicated in various types of cancer. HER2 is overexpressed in approximately 15%–20% of all breast cancers1 and is correlated with poor prognosis.2 HER receptors comprise an extracellular domain, a single transmembrane domain, and an intracellular tyrosine kinase domain.3 A disintegrin and metalloproteinases (ADAMs) shed the ligands that are needed for HER member activation. Eleven ligands are known to bind to the different receptors of the family, as shown in Figure 1;3 however, HER2 does not have a known ligand.4 Ligand binding induces a conformational change in HER receptors 1, 3, and 4, which exposes the dimerization domain. This facilitates homodimerization or heterodimerization and transphosphorylation of the tyrosine kinase domains.5 Subsequently, downstream signaling pathways, most prominently the phosphatidylinositide 3-kinase and mitogen-activated protein kinase pathways, are activated and promote survival and proliferation.6–8 HER2 adopts a constant “open” conformation, with the dimerization domain being always available.9 It was shown to be the preferred dimerization partner within the HER receptor network and it can also form potent homodimers.10


Page 1 of 9
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs